Gene editing biotech company Cellectis and AstraZeneca have partnered to accelerate the development of gene editing therapeutics, with a focus on oncology, immunology, and rare diseases.
Under the terms of the agreement, Cellectis will receive an initial payment of USD 105 million, including a USD 25 million upfront fee and USD 80 million in equity investment, resulting in a 22% stake in Cellectis. An additional USD 140 million equity investment by AstraZeneca is expected in early 2024, which will result in a 44% stake in Cellectis.
The partnership will leverage Cellectis' gene editing technologies and manufacturing capabilities to create novel treatments across 25 exclusive genetic targets, which could result in up to 10 potential products for development. These products may also be eligible for an option fee for an investigational new drug and milestone payments, ranging from USD 70 million to USD 220 million for each candidate, based on progress in development, regulatory approval, and sales. The partnership also aims at expanding AstraZeneca's cell therapy offerings for cancer and advancing genomic medicines for rare diseases.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.